DEF: Mainz Biomed Seeks Shareholder Nod for Major Strategic Shift

Mainz Biomed N.V. calls an extraordinary shareholder meeting to approve a significant capital raise, a reverse stock split, a name change to Quantum Cyber N.V., and a new board, signaling a major strategic pivot towards quantum computing.

Summary

• Shareholders are asked to ratify Reliant CPA PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• Approval is sought for the issuance of Ordinary Shares underlying Series A, B, C, D, and E Preferred Shares to David E. Lazar, to comply with Nasdaq Listing Rules 5635(b) and 5635(d).
• David E. Lazar has already invested $3 million for Series A, B, and C Preferred Shares, convertible into 27 million Ordinary Shares, and will invest an additional $3 million for Series D and E Preferred Shares, convertible into 450 million Ordinary Shares, upon shareholder approval.
• The total investment of $6 million from Mr. Lazar would result in his ownership of over 95% of the company's issued and outstanding Ordinary Shares on a fully diluted basis.
• Proposed amendments to the Articles of Association include authorizing the conversion of preferred shares, changing the company name to Quantum Cyber N.V., and increasing authorized Ordinary Shares from 45 million to 900 million (post-Reverse Share Split Basis) and Preferred Shares from 5 million to 100 million (post-Reverse Share Split Basis).
• Shareholders will vote on authorizing the Board to effect a reverse share split of Ordinary and Preferred Shares at a ratio ranging from 1:2 to 1:100, at the Board's discretion, primarily to regain Nasdaq's minimum bid price requirement.
• The company received a Nasdaq non-compliance notice on March 20, 2026, due to its share price being below $1.00 for 30 consecutive trading days; the closing price was $0.48 on March 23, 2026.
• Four new directors are nominated: David Lazar (Executive Director and CEO), Robert Liscouski (Non-Executive Director), David Natan (Non-Executive Director), and Avraham Ben-Tzvi (Non-Executive Director).
• Current CEO Guido Baechler and other directors (Dr. Heiner Dreismann, Hans Hekland, Greggory Tibbits) are expected to resign if the new director appointments are approved.
• An amendment to the 2025 Omnibus Incentive Plan is proposed to increase the number of Ordinary Shares awardable thereunder from 1,467,021 to 10,000,000.
• Amendments to the Remuneration Policy are proposed, including increasing annual equity awards for directors to 500,000 shares/rights, raising the maximum fixed annual compensation for non-executive directors to $150,000, and allowing a bonus grant of up to 2.0% of fully-diluted outstanding Ordinary Shares for the non-executive chairman.
• Shareholder approval is sought for Board resolutions related to the Securities Purchase Agreement and the transactions therein, as required by Dutch Civil Code.
• The company intends to sell intellectual property related to its colorectal cancer products (ColoAlert and NextGen) around the Second Closing, using proceeds for expenses, a 3-month operational 'Backstop,' and a dividend to shareholders (excluding Mr. Lazar).
• Settlement Agreements with the current CEO, CFO, and three directors will result in aggregate payments of approximately $1.9 million upon the Final Closing, covering accrued salary, bonuses, healthcare continuation, and severance.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with significant caution due to the extreme dilution for existing shareholders, the company's precarious Nasdaq listing status despite a recent reverse split, and the highly speculative nature of the proposed strategic pivot to quantum computing without concrete plans.

Positives

• The $6 million capital injection from David E. Lazar provides crucial liquidity for the company's operations and liabilities.
• The proposed strategic pivot towards the quantum computing industry, supported by new board members with relevant expertise, offers potential for future growth and diversification.
• The reverse stock split, if successful, could help the company regain compliance with Nasdaq's minimum bid price requirement, preventing delisting.
• The expanded Omnibus Incentive Plan and revised Remuneration Policy aim to attract and retain high-quality management and directors, which is essential for executing a new strategy.

Negatives

• The investment from David E. Lazar will result in extreme dilution, with his ownership potentially exceeding 95% of the company on a fully diluted basis, significantly diminishing the value and control of existing shareholders.
• The company's share price is currently $0.48, below Nasdaq's $1.00 minimum bid, despite a previous 1-for-40 reverse stock split in December 2024, indicating persistent market challenges.
• The strategic shift to quantum computing is currently exploratory, with no formal agreements or acquisitions, introducing significant uncertainty and risk to the company's future business model.
• The proposed increases in executive and director compensation, including a potential 2.0% bonus grant of fully-diluted shares for the non-executive chairman, appear substantial given the company's financial situation and the severe dilution faced by shareholders.
• The company faces potential cessation of operations or asset sale if the proposals are not approved and additional capital cannot be raised, highlighting a precarious financial position.

Risks

• Failure to approve the Nasdaq Compliance Proposal, Additional Amendment Proposal, Reverse Split Amendment Proposal, and Director Appointment Proposals could prevent the Final Closing of the $3 million investment, leading to an inability to raise additional capital and potentially forcing the company to cease operations, sell substantial assets, or enter receivership.
• The reverse share split may not effectively increase the market price of Ordinary Shares proportionately or sustain it above the Nasdaq minimum bid price, potentially leading to continued non-compliance and delisting.
• Delisting from Nasdaq could result in trading on less liquid markets (e.g., OTC Bulletin Board or pink sheets) and subject the shares to 'penny stock' rules, making them more difficult to trade and reducing market efficiency.
• The negative perception associated with reverse share splits among investors, analysts, and market participants could adversely affect the company's stock price and liquidity.
• The significant increase in authorized Ordinary and Preferred Shares, combined with the conversion of preferred shares, will lead to substantial dilution for existing shareholders, potentially causing a decline in the trading price of Ordinary Shares.
• The issuance of authorized but unissued shares could be used to deter a potential takeover, which might otherwise be beneficial to shareholders by offering a premium for their shares.
• The proposed strategic pivot to the quantum computing industry is speculative, with no formal arrangements or agreements for business or asset acquisition, meaning the company might not successfully enter this new industry.
• Directors and officers have financial and personal interests in the approval of the proposals (e.g., re-appointment, incentive plan awards, settlement payments), which could create conflicts of interest with the broader shareholder base.

Future Outlook

The company intends to continue its operations in developing in-vitro diagnostic tests for colorectal and pancreatic cancer while actively exploring new opportunities in the quantum computing industry. This strategic pivot is aimed at leveraging the expertise of new director nominees and seeking growth. The successful approval of the proposals is critical for securing additional capital and enabling this strategic shift, although no formal agreements have been reached in the quantum computing space.

Management Comments

• "The Board has determined that each proposal listed above is in the best interests of the Company and its shareholders and has approved each proposal."
• "The Board recommends a vote FOR the Auditor Ratification Proposal (Proposal 1), FOR the Nasdaq Compliance Proposal (Proposal 2), FOR the Additional Amendment Proposal (Proposal 3), FOR the Reverse Split Amendment Proposal (Proposal 4), FOR each of the Director Appointment Proposals (Proposal 5 through Proposal 8), FOR the Incentive Plan Amendment Proposal (Proposal 9), FOR the Remuneration Policy Proposal (Proposal 10) and FOR the Board Resolution Approval Proposal (Proposal 11)."
• "Although our intention is to continue our operations for the development of in-vitro diagnostic tests for the early detection of colorectal and pancreatic cancer, we intend to explore new opportunities for one or more business segments. We believe the quantum computing industry holds exciting opportunities for growth, and based on the strengths of our director nominees in the quantum computing industry, we believe that this parallel direction for our Company will likely be in the best interests of our shareholders."
• "Although we and our director nominees have discussed several opportunities in the quantum computing industry with third parties, we have not reached any formal arrangements or agreements to acquire a business or assets in the space, and we might not ever do so."
• "The Board believes that the Additional Amendment Proposal is necessary to reach the Final Closing (as it is a condition precedent to the Final Closing) and for the future direction of the Company."
• "We expect that the Reverse Share Split would increase the bid price per Ordinary Share and reduce the risk of our shares trading below $1.00 in the future, thereby satisfying or maintaining this listing requirement. However, the Reverse Share Split might not have that effect, initially or in the future, and even if we undertake it, we might not be able to regain compliance with the Minimum Bid Requirement or to maintain such compliance if we do."
• "The Board believes that approving the amendment to the 2025 Omnibus Incentive Plan is in the best interests of the shareholders."
• "The Board and the Compensation Committee believe that the policies and procedures articulated in the amended and restated Remuneration Policy will help the Company attract and retain high-quality directors."

Industry Context

StockSavvy.ai notes that the proposed strategic pivot from biomedical diagnostics (colorectal and pancreatic cancer tests) to quantum computing represents a significant and unusual shift. While the diagnostics market is established, the quantum computing industry is nascent but holds high growth potential. The company is attempting to leverage new board members' expertise in this area, a common strategy for companies seeking to enter new, high-tech sectors. However, the lack of formal agreements in quantum computing suggests this is an exploratory move rather than a concrete business plan, which introduces considerable uncertainty compared to established industry players.

Comparison to Industry Standards

• The proposed reverse stock split, intended to regain Nasdaq compliance, is a common tactic for companies facing minimum bid price deficiencies. However, its effectiveness is mixed across industries; for example, companies like Sow Good (SOWG) or Kala Bio Inc. (KALA) (where David Lazar has also served as CEO/Chairman) have also faced similar challenges and used reverse splits with varying long-term success in maintaining share price.
• The significant dilution (Lazar potentially owning >95% fully diluted) is an extreme outcome for a capital raise, far exceeding typical private placement dilutive impacts seen in the biotech or tech sectors, where strategic investors usually take substantial but not near-total control unless it's a distressed asset sale or a full acquisition.
• The proposed executive and director remuneration increases, particularly the non-executive chairman's potential bonus grant of up to 2.0% of fully-diluted outstanding shares, appear exceptionally high compared to global benchmarks for non-executive roles, even in high-growth tech companies. This level of equity compensation for a non-executive chairman is more akin to founder or executive-level incentives in early-stage ventures rather than a typical public company board structure.

Management Changes

Corporate Governance

Legal Proceedings

• No material action, suit, inquiry, notice of violation, proceeding or investigation is pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority as of the Effective Date.
• None of the Company's directors or executive officers have been involved in any legal proceedings described in subparagraph (f) of Item 401 of Regulation S-K during the past ten years.

Related Party Transactions

• Securities Purchase Agreement with David E. Lazar, who is a current non-executive director and nominated as Executive Director and CEO, involving a $6 million investment and potential ownership of over 95% of the company on a fully diluted basis.
• Settlement Agreements with the current Chief Executive Officer, Chief Financial Officer, and three other directors, providing for aggregate payments of approximately $1.9 million upon the Final Closing, which is contingent on shareholder approval of several proposals.
• A Voting Agreement was entered into with David E. Lazar and certain stockholders (including officers and directors) owning approximately 12.4% of outstanding Ordinary Shares, committing them to vote in favor of the Board-recommended proposals.
• Current directors nominated for reappointment have a personal interest in the Director Appointment Proposals.
• Directors are eligible to receive awards under the 2025 Omnibus Incentive Plan, which would not be available if the Incentive Plan Amendment Proposal is not approved.
• Directors are eligible to receive additional compensation for their services under the terms of the amended and restated Remuneration Policy if the Remuneration Policy Amendment is approved.

Stakeholder Impact

• Shareholders face extreme dilution (over 95% ownership by new investor David Lazar on a fully diluted basis) if proposals are approved, significantly reducing their proportional ownership and voting power. They may receive a dividend from the asset sale (excluding Mr. Lazar).
• Employees, particularly executive officers and directors, will see significant management changes, with the current CEO and CFO expected to resign. The expanded incentive plan aims to attract and retain talent, offering potential equity awards.
• Customers of the company's colorectal cancer diagnostic products (ColoAlert and NextGen) may be impacted by the planned sale of related intellectual property. The company intends to continue developing pancreatic cancer diagnostic products.
• Creditors may benefit from the $6 million capital injection, which provides immediate liquidity, although the company acknowledges that the purchase price may not be sufficient to satisfy all existing obligations.

Next Steps

• Shareholders to vote on 11 proposals at the Extraordinary Shareholders Meeting on April 22, 2026.
• If proposals are approved, the Second Closing of David Lazar's $3 million investment will occur.
• If proposals are approved, the company name will change to Quantum Cyber N.V.
• If proposals are approved, David Lazar will be appointed CEO and Executive Director, and Robert Liscouski, David Natan, and Avraham Ben-Tzvi will be appointed Non-Executive Directors, with current CEO and other directors resigning.
• The Board may, at its discretion, effect a reverse share split at a ratio between 1:2 and 1:100 to regain Nasdaq minimum bid price compliance.
• The company intends to sell intellectual property related to its colorectal cancer business (ColoAlert and NextGen) around the Second Closing.
• The company will continue developing pancreatic cancer diagnostic products.
• The company will explore new opportunities in the quantum computing industry.
• The company will file a Current Report on Form 8-K with final voting results within four business days after the Shareholders Meeting.
• If proposals are not approved, the company will use reasonable best efforts to call a Second Meeting within 90 days.

Key Dates

Recommendation

The proposed transactions, while injecting $6 million in capital, involve an extraordinary level of dilution, effectively transferring over 95% ownership to a single investor, David Lazar, on a fully diluted basis. This fundamentally alters the ownership structure and significantly diminishes the value of existing shareholder equity. The company's persistent Nasdaq non-compliance, despite a prior 1-for-40 reverse split, coupled with the highly speculative and unproven pivot to quantum computing, introduces immense uncertainty and risk. The substantial increases in executive and director compensation, particularly for the non-executive chairman, appear misaligned with the company's distressed financial state and the severe dilution imposed on current shareholders. Given the extreme dilution, the speculative nature of the new business direction, and the ongoing listing challenges, existing shareholders face a high probability of substantial capital loss.

Keywords

Mainz Biomed, Quantum Cyber N.V., Proxy Statement, Shareholder Meeting, Reverse Stock Split, Capital Raise, Preferred Shares, Dilution, Nasdaq Compliance, Corporate Governance, Board Changes, Executive Compensation, Quantum Computing, Biomedical Diagnostics, ColoAlert, David Lazar, Robert Liscouski, Strategic Shift